Lawrence Wang is a Managing Director who joined Vivo in 2015. Before joining Vivo, Lawrence was a Managing Director at Primavera Capital Group. At Primavera, he led execution on several investments including Chemspec International, Oasis International Hospital, Focus Media, Shanda Games and China XLX Fertilizer Corporation.
Prior to Primavera, Lawrence was Executive Director and head of Asia healthcare for Macquarie Capital where he was responsible for healthcare advisory and on-balance sheet investments for Macquarie Capital. While at Macquarie, Lawrence led and executed Fortis’ $4.3bn SGD voluntary general offer for Parkway Holdings as well as Macquarie’s first bookrun NYSE IPO of China Cord Blood Corporation.
Prior to Macquarie, Lawrence was an Executive Director at Goldman Sachs Hong Kong, responsible for on-balance sheet investments for investment banking division’s principal investment group, GS Direct Asia, and healthcare advisory coverage for Asia ex-Japan region. Lawrence led and executed GS Direct Asia’s $22.5mm investment in Shenzhen Hepalink as well as the healthcare IPO’s of Mindray, Simcere and Nepstar.
Lawrence was also a Vice President, Investment Banking Healthcare Group for Goldman Sachs in New York, having advised and executed on $3.7bn sellside and staple-on financing for VWR International’s sale to MDP, Anthem’s $16bn acquisition of WellPoint, and WellPoint’s $6.5bn acquisition of WellChoice, among others.
Lawrence holds a Bachelor of Arts in Biology and Economics and a Doctor of Medicine from Boston University and an MBA from MIT Sloan School of Management.